Identification of virulence associated regions RD1 and RD5 leading to improve vaccine of M. bovis BCG and M. microti
US7883712B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Apr 1, 2003 |
| Grant date | Feb 8, 2011 |
| Priority date | — |
| Expiry date | Oct 27, 2026 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/523
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a strain of M. bovis BCG or M. microti, wherein said strain has integrated part or all of the RD1 region responsible for enhanced immunogenicity of the tubercle bacilli, especially the ESAT-6 and CFP-10 genes. These strains will be referred as the M bovis BCG::RDI or M. microti::RD1 strains and are useful as a new improved vaccine for preventing tuberculosis and as a therapeutical product enhancing the stimulation of the immune system for the treatment of bladder cancer. These strains are also useful for the expression and presentation of heterologous antigens and molecule that are of therapeutic or prophylactic interest.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.